Phase 2 trial in 119 men with de novo metastatic prostate cancer after 6 months of systemic therapy: adding surgery or radiotherapy to the primary tumour did not improve PFS (median 17.9 vs 14.8 months; HR 0.89, p=0.6). Grade 3 toxicity 6.7% vs 0%.
RCTn = 119
Chapin et al. A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer